Piriʙedil

When ATH:
C04AX13

Pharmacological action.
Antiparkinsonian.

Application.

As an additional symptomatic treatment for chronic cognitive impairment, and neurosensory deficiency in aging (incl. disorders of attention and memory); Parkinson's disease as monotherapy (when forms, mostly accompanied by tremor) or in combination with levodopa (at the beginning of the disease or secondary to forms, accompanied by tremor); as adjunctive therapy for intermittent claudication due to occlusive arterial disease of the lower extremities (Stage II of Leriche and Fontaine classification); treatment of symptoms of ophthalmic diseases ischemic (incl. reduced visual acuity, narrowing of the visual field, decrease the contrast of colors).

Contraindications.

Hypersensitivity, hypotension, collapse, myocardial infarction (acute phase), co-administration with neuroleptics with pronounced antipsychotic properties (except clozapine), pregnancy, lactation.

Pregnancy and breast-feeding.

Contraindicated in pregnancy (adequate and well-controlled studies on the use during pregnancy have not been conducted) and during lactation.

Side effects.

Anxiety, excitation, drowsiness, mental disorders; orthostatic hypotension; nausea, vomiting, flatulence.

Cooperation.

Dopamine antagonists, incl. neuroleptics (fenotiazinы, butyrofenonы, tïoksantenı) metoclopramide, may reduce the effectiveness of (mutually).

Overdose.

Symptoms: vomiting.

Treatment: gastric lavage, simptomaticheskaya therapy.

Dosing and Administration.

Inside, after meal, 50 mg/day at a time, If you need to 50 mg 2 once a day. Parkinson's Disease: monotherapy — 150-250 mg/day in the 3-5 techniques; in combination with levodopa is 100-150 mg in 2-3 reception.

Precautions.

In patients with high blood pressure need more antihypertensive therapy.

If necessary, neuroleptics in patients with Parkinson's disease, receiving piribedil, the last dose should be reduced gradually to a complete abolition. The sudden cancellation piribedil can cause neuroleptic malignant syndrome.

There is a mutual antagonism between piribedilom and antiemetic drugs group dopamine antagonists (piribedil joint reception and antiemetics group centrally acting dopamine antagonists is not recommended due to the risk of reducing the effectiveness of both drugs; Nonetheless, in the event of digestive disorders, caused by taking piribedil, possible appointment of antiemetics, acting on peripheral dopamine receptors (Domperidone).

If you experience while taking piribedil being very sleepy (until suddenly falling asleep) should consider dose reduction or drug discontinuation.